Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs CoHKSE:09887 +8.04%10 Return-on-Tangible-Equity is -13.17% as of Dec. 2025. GuruFocus rates HKSE:09887 with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,199 Biotechnology companies, Nanjing Leads Biolabs Co ranks better than 51.79% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Nanjing Leads Biolabs Co's annualized net income for the quarter that ended in Dec. 2025 was HK$-99.5 Mil. Nanjing Leads Biolabs Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$755.2 Mil. Therefore, Nanjing Leads Biolabs Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -13.17%.
The historical rank and industry rank for Nanjing Leads Biolabs Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:09887'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -38.73 Med: -27.81 Max: -27.81
Current: -38.73
During the past 3 years, Nanjing Leads Biolabs Co's highest Return-on-Tangible-Equity was -27.81%. The lowest was -38.73%. And the median was -27.81%.
HKSE:09887's Return-on-Tangible-Equity is ranked better than 51.79% of 1199
companies
in the Biotechnology industry
Industry Median: -41.98
vs HKSE:09887: -38.73
Nanjing Leads Biolabs Co (HKSE:09887) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Nanjing Leads Biolabs Co Return-on-Tangible-Equity Related Terms
Nanjing Leads Biolabs Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Nanjing Leads Biolabs Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co Return-on-Tangible-Equity Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
Return-on-Tangible-Equity
0.00
0.00
-27.81
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Return-on-Tangible-Equity
0.00
0.00
-90.99
-183.00
-13.17
HKSE:09887 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -13.17% mean?
Nanjing Leads Biolabs Co (HKSE:09887) has a Return-on-Tangible-Equity of -13.17% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nanjing Leads Biolabs Co and its competitors. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #578 out of 1199 companies in the Biotechnology industry, placing it in the top 48.2%.
Is Nanjing Leads Biolabs Co's Return-on-Tangible-Equity too high?
Nanjing Leads Biolabs Co's current Return-on-Tangible-Equity is -13.17%. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #578 out of 1199 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #578 out of 1199 companies for Return-on-Tangible-Equity. This puts Nanjing Leads Biolabs Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current Return-on-Tangible-Equity is -13.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (HKSE:09887) has a current Return-on-Tangible-Equity of -13.17%. The current Return-on-Tangible-Equity is -13.17%. Nanjing Leads Biolabs Co's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (HKSE:09887), the current Return-on-Tangible-Equity is -13.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
10GF Score
Get the complete analysis for HKSE:09887
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09887 has been successfully added to your 
